BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15954913)

  • 1. Biomarkers of inflammation and progression of chronic kidney disease.
    Tonelli M; Sacks F; Pfeffer M; Jhangri GS; Curhan G;
    Kidney Int; 2005 Jul; 68(1):237-45. PubMed ID: 15954913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.
    Tonelli M; Moyé L; Sacks FM; Cole T; Curhan GC;
    J Am Soc Nephrol; 2003 Jun; 14(6):1605-13. PubMed ID: 12761262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease.
    Tonelli M; Isles C; Craven T; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; West M; Packard C; Curhan GC
    Circulation; 2005 Jul; 112(2):171-8. PubMed ID: 15998677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study.
    Sarnak MJ; Poindexter A; Wang SR; Beck GJ; Kusek JW; Marcovina SM; Greene T; Levey AS
    Kidney Int; 2002 Dec; 62(6):2208-15. PubMed ID: 12427147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
    Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC
    Am J Kidney Dis; 2004 Nov; 44(5):832-9. PubMed ID: 15492949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention.
    Fathi RB; Gurm HS; Chew DP; Gupta R; Bhatt DL; Ellis SG
    Am Heart J; 2005 Dec; 150(6):1190-7. PubMed ID: 16338257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
    Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
    Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
    Ruggenenti P; Perna A; Mosconi L; Pisoni R; Remuzzi G
    Kidney Int; 1998 May; 53(5):1209-16. PubMed ID: 9573535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
    Ruggenenti P; Perna A; Mosconi L; Matalone M; Pisoni R; Gaspari F; Remuzzi G
    Kidney Int Suppl; 1997 Dec; 63():S54-7. PubMed ID: 9407422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease.
    Lee BT; Ahmed FA; Hamm LL; Teran FJ; Chen CS; Liu Y; Shah K; Rifai N; Batuman V; Simon EE; He J; Chen J
    BMC Nephrol; 2015 May; 16():77. PubMed ID: 26025192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin-induced arrest in progression of renal disease.
    Vidt DG; Cressman MD; Harris S; Pears JS; Hutchinson HG
    Cardiology; 2004; 102(1):52-60. PubMed ID: 15073451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus.
    Lin J; Hu FB; Rimm EB; Rifai N; Curhan GC
    Kidney Int; 2006 Jan; 69(2):336-42. PubMed ID: 16408124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation].
    Gonzálvez M; Ruiz Ros JA; Pérez-Paredes M; Lozano ML; Giménez DM; Martínez-Corbalán F; Carnero A; Cubero T; Gómez AE; Vicente V
    Rev Esp Cardiol; 2004 Oct; 57(10):916-23. PubMed ID: 15469788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation.
    Aveles PR; Criminácio CR; Gonçalves S; Bignelli AT; Claro LM; Siqueira SS; Nakao LS; Pecoits-Filho R
    Nephron Clin Pract; 2010; 116(4):c294-9. PubMed ID: 20639676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial stiffness and declines in individuals with normal renal function/early chronic kidney disease.
    Tomiyama H; Tanaka H; Hashimoto H; Matsumoto C; Odaira M; Yamada J; Yoshida M; Shiina K; Nagata M; Yamashina A
    Atherosclerosis; 2010 Sep; 212(1):345-50. PubMed ID: 20594557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance.
    Axelsson J; Bergsten A; Qureshi AR; Heimbürger O; Bárány P; Lönnqvist F; Lindholm B; Nordfors L; Alvestrand A; Stenvinkel P
    Kidney Int; 2006 Feb; 69(3):596-604. PubMed ID: 16395259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pravastatin in people with diabetes and chronic kidney disease.
    Tonelli M; Keech A; Shepherd J; Sacks F; Tonkin A; Packard C; Pfeffer M; Simes J; Isles C; Furberg C; West M; Craven T; Curhan G
    J Am Soc Nephrol; 2005 Dec; 16(12):3748-54. PubMed ID: 16251235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.